Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GBT Global Blood Therapeutics
Do not show
Hide blank lines
Total revenue
50.46% 71.55M 41.28% 55.16M 57.31% 194.75M 35.85% 56.1M
Operating revenue
50.46% 71.55M 41.28% 55.16M 57.31% 194.75M 35.85% 56.1M
Cost of revenue
88.9% 1.41M 80.65% 1.06M 66.97% 3.32M 20.21% 1.15M
Gross profit
49.84% 70.14M 40.68% 54.11M 57.15% 191.43M 36.22% 54.95M
Operating expense
29.22% 145.86M 15.97% 127.37M 30.92% 479.12M 38.31% 137.91M
Selling and administrative expenses
32.73% 81.09M 26.4% 74.53M 26.62% 266.99M 34.62% 78.94M
Research and development costs
25.09% 64.78M 3.89% 52.83M 36.75% 212.14M 43.58% 58.97M
Operating profit
-14.61% -75.73M -2.66% -73.26M -17.83% -287.69M -39.73% -82.96M
Net non-operating interest income expense
-91.8% -6.74M -129.32% -7.71M -270.99% -14.75M -81.62% -4.25M
Non-operating interest income
914.63% 1.66M 51.98% 500K -87.66% 720K -- --
Non-operating interest expense
128.5% 8.4M 122.42% 8.21M 57.68% 15.47M -- --
Total other finance cost
-- -- -- -- -- -- 81.62% 4.25M
Other net income (expense)
2166.67% 186K -38.83% -286K -130.62% -177K -296.77% -369K
Special income (charges)
-- -- -- -- -- 0 -- 0
Other non- operating income (expenses)
2166.67% 186K -38.83% -286K 56.4% -177K -296.77% -369K
Income before tax
-18.23% -82.28M -8.44% -81.25M -22.24% -302.61M -41.7% -87.58M
Income tax
192K 171K 477K
Net income
-18.51% -82.47M -8.67% -81.42M -22.43% -303.09M -41.7% -87.58M
Net income continuous Operations
-18.51% -82.47M -8.67% -81.42M -22.43% -303.09M -41.7% -87.58M
Minority interest income
Net income attributable to the parent company
-18.51% -82.47M -8.67% -81.42M -22.43% -303.09M -41.7% -87.58M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-18.51% -82.47M -8.67% -81.42M -22.43% -303.09M -41.7% -87.58M
Basic earnings per share
-12.5% -1.26 -4.13% -1.26 -19.06% -4.81 -36% -1.36
Diluted earnings per share
-12.5% -1.26 -4.13% -1.26 -19.06% -4.81 -36% -1.36
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Hot List
SymbolLatest price%Chg